In November 2025, Cytokinetics announced that additional late-stage aficamten trial data were presented at major cardiovascular conferences, highlighting the drug's positive effects across multiple ...

Motilal Oswal Financial Services recommends Reliance Industries and HCL Tech from the large-cap basket, while BEL and M&M Financial are top bets from mid-cap ...

Facebook users shared a story claiming a Democratic Party-led "deep state assassination plot" involving the Pennsylvania U.S.

Their aim is to reduce unnecessary drug use by identifying medicines suited to an individual’s genetic profile ...

Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK ...

Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.

NEW ORLEANS -- A polypill that combines three of the four mainstays of treatment for heart failure with reduced ejection fraction improved cardiac function and reduced the risks for serious medical ...

AIOCD asks traders to strictly comply with the ban on 35 FDCs: Peethaambaran Kunnathoor, Chennai Friday, November 21, 2025, ...

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...

Ventricular electrical storm (ES) urgently needs standardized definitions and high-quality evidence to guide diagnosis, risk ...

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

The road to wellness frequently depends on lifesaving pills, yet for millions, these same medications deliver a baffling ...